Pharmas shrug off tariff threats

Two ASX-listed companies have responded to looming US-imposed pharmaceutical tariffs, with one pricing in an impact on hospital products Sleep apnoea company Fisher and Paykel Healthcare says it’s expecting a 75-basis point impact from US President Donald Trump’s tariffs on hospital products sourced from New Zealand, but its outlook remains unchanged. The NZ-based company is